N2OFF (NITO) 10-Q 15 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2020shares
Document And Entity Information
Entity Registrant Name	Save Foods Inc.
Entity Central Index Key	0001789192
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	10,209,487
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 180,003	$ 290,815
Restricted Cash	37,027	38,194
Accounts receivable, net		64,003
Inventories	11,267	16,302
Other current assets	26,159	15,300
Total Current assets	254,456	424,614
Right Of Use asset arising from operating lease	37,314	48,982
Property and Equipment, Net	73,703	81,119
Funds in Respect of Employee Rights Upon Retirement	109,871	109,955
Total assets	475,344	664,670
Current Liabilities
Short-term loan from banking institution	7,049	7,230
Accounts payable	219,145	235,864
Other accounts liabilities	392,148	380,732
Total current liabilities	618,342	623,826
Convertible Loans	403,011	285,917
Long term from banking institution	12,717	14,955
Liability for employee rights upon retirement	142,357	142,091
Total liabilities	1,176,427	1,066,789
Stockholders' Deficit
Common stocks of US$ 0.0001 par value each ("Common Stocks"): 495,000,000 shares authorized as of March 31, 2020 and December 31, 2019; issued and outstanding 10,209,487 shares as of March 31, 2020 and December 31, 2019.	1,021	1,021
Preferred stocks of US$ 0.0001 par value ("Preferred stocks"): 5,000,000 shares authorized as of March 31, 2020 and December 31, 2019; issued and outstanding 0 shares as of March 31, 2020 and December 31, 2019.
Additional paid-in capital	10,398,420	10,328,696
Foreign currency translation adjustments	(26,275)	(26,275)
Accumulated deficit	(11,050,155)	(10,684,508)
Stockholders' Equity	(676,989)	(381,066)
Non-controlling interests	(24,094)	(21,053)
Total stockholders' deficit	(701,083)	(402,119)
Total liabilities and stockholders' deficit	$ 475,344	$ 664,670

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stocks, par value	$ 0.0001	$ 0.0001
Common stocks, shares authorized	495,000,000	495,000,000
Common stocks, shares issued	10,209,487	10,209,487
Common stocks, shares outstanding	10,209,487	10,209,487
Preferred stocks, par value	$ 0.0001	$ 0.0001
Preferred stocks, shares authorized	5,000,000	5,000,000
Preferred stocks, shares issued	0	0
Preferred stocks, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues from sales of products	$ 63,566	$ 129,733
Cost of sales	(20,775)	(34,041)
Gross profit	42,791	95,692
Research and development expenses	(157,636)	(131,826)
Selling and marketing expenses	(28,937)	(146,562)
General and administrative expenses	(218,079)	(163,148)
Operating loss	(361,861)	(345,844)
Financing expenses, net	(7,202)	(13,502)
Net loss	(369,063)	(359,346)
Less: Net loss attributable to non-controlling interests	3,416	3,584
Net loss attributable to the Company	$ (365,647)	$ (355,762)
Loss per share (basic and diluted)	$ (0.04)	$ (0.04)
Basic and diluted weighted average number of shares of common stock outstanding	10,209,487	9,521,981

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Proceeds on Account of shares [Member]	Accumulated Deficit [Member]	Total Company's Stockholders' Equity [Member]	Non-controlling Interest [Member]	Total
Beginning balance at Dec. 31, 2018	$ 923	$ 8,851,670	$ (26,275)	$ 105,000	$ (8,713,091)	$ 218,227	$ (6,712)	$ 211,515
Beginning balance, shares at Dec. 31, 2018	9,228,339
Issuance of shares for cash	$ 61	561,606		(105,000)		456,667		456,667
Issuance of shares for cash, shares	605,563
Stock based compensation		67,235				67,235	720	67,955
Comprehensive loss					(355,762)	(355,762)	(3,584)	(359,346)
Ending balance at Mar. 31, 2019	$ 984	9,480,511	(26,275)		(9,068,853)	386,367	(9,576)	376,791
Ending balance, shares at Mar. 31, 2019	9,833,902
Beginning balance at Dec. 31, 2019	$ 1,021	10,328,696	(26,275)		(10,684,508)	(381,066)	(21,053)	(402,119)
Beginning balance, shares at Dec. 31, 2019	10,209,487
Stock based compensation		35,028				35,028	375	35,403
Value of warrant issued in convertible loans		34,696				34,696		34,696
Comprehensive loss					(365,647)	(365,647)	(3,416)	(369,063)
Ending balance at Mar. 31, 2020	$ 1,021	$ 10,398,420	$ (26,275)		$ (11,050,155)	$ (676,989)	$ (24,094)	$ (701,083)
Ending balance, shares at Mar. 31, 2020	10,209,487

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (369,063)	$ (359,346)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:
Depreciation and amortization	19,084	3,757
Increase in liability for employee rights upon retirement	266	6,021
Stock based compensation	35,403	67,955
Interest on convertible loans	17,325	1,011
Decrease (increase) in accounts receivable	64,003	(27,211)
Decrease in inventory	5,035	12,441
Increase in other current assets	(10,859)	(20,377)
Decrease in accounts payable	(16,719)	(50,669)
Increase in other accounts payable	21,889	39,524
Net cash used in operating activities	(233,636)	(326,894)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase (decrease) in funds in respect of employee rights upon retirement	84	(4,484)
Net cash provided by (used in) investing activities	84	(4,484)
CASH FLOWS FROM FINANCING ACTIVITIES:
Secured promissory notes	135,000
Repayments of right to use asset arising from operating lease	(10,473)
Repayments of long term banking institute	(1,787)	(5,795)
Proceeds from stock issued for cash		456,667
Net cash provided by financing activities	122,740	450,872
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(110,812)	119,494
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	290,815	439,806
CASH AND CASH EQUIVALENTS AT END OF PERIOD	180,003	559,300
Non cash transactions:
Issuance of shares in exchange for proceeds received in prior periods		105,000
Issuance of warrants in convertible loans	$ 34,696

General

General	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	NOTE 1 - GENERAL Save Foods Inc. (the “Company”) was incorporated on April 1, 2009, under the laws of the State of Delaware. On April 27, 2009, the Company acquired from its stockholders all of the issued and outstanding shares of Save Foods Ltd (formerly Pimi Agro Cleantech Ltd). (hereinafter: “Save Foods Israel”), including preferred and ordinary shares. Save Foods Israel was incorporated in 2004 and commenced its operations in 2005. Save Foods Israel develops, produces, and focuses on delivering innovative solutions for the food industry aimed at improving food safety and prolonging shelf life of fresh produce. In February 2010, the Company’s shares of common stock began quotation on the OTC Bulletin Board under the symbol “PIMZ.OB”. As of the date of the financial statements the Company’s shares of common stock are quoted on the OTC Pink under the symbol “SAFO”. Going Concern Since its incorporation (April 1, 2009), the Company has not had any operations other than those carried out by Save Foods Israel. The development and commercialization of Save Foods Israel’s products will require substantial expenditures. Save Foods Israel and the Company have not yet generated sufficient revenues from their operations to fund the Group activities and are therefore dependent upon external sources for financing their operations. There can be no assurance that Save Foods Israel and the Company will succeed in obtaining the necessary financing to continue their operations. As of March 31, 2020, the Company had $180,003 in cash, a negative working capital of $363,886 and an accumulated deficit of $11,050,155. The Company will need to secure additional capital in the future in order to meet its anticipated liquidity needs primarily through the sale of additional Common Stock or other equity securities and/or debt financing. Funds from these sources may not be available to the Company on acceptable terms, if at all, and the Company cannot give assurance that it will be successful in securing such additional capital. The Company focuses its solutions towards vegetables and fruits which are considered the largest in terms of worldwide consumption. Among other things, the Company tries to cooperate with major fruit packing houses in Israel and abroad. As of balance sheet date, the Company had not signed any significant agreements. These factors raise substantial doubt about Save Foods Israel and the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (SARS-CoV-2) to be a global pandemic (COVID-19), which continues to spread throughout the United States and around the world. The COVID-19 pandemic is having significant effects on global markets, supply chains, businesses, and communities. Specific to the Company, COVID-19 may impact various parts of its 2020 operations and financial results including but not limited to reduction in sales, difficulties in obtaining additional financing, or potential shortages of personnel. The Company believes it is taking appropriate actions to mitigate the negative impact. However, the full impact of COVID-19 is unknown and cannot be reasonably estimated as these events occurred subsequent to year end and are still developing.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Unaudited Interim Financial Statements The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the for three-months ended March 31, 2020. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2020. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates. Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ Alternative Reporting System, for the year ended December 31, 2019 Principles of Consolidation The consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to the going concern assumptions and convertible loans. Recent Accounting Pronouncements In June 2016, FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. In November 2018, FASB issued ASU No. 2018-19, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses”, which amends the scope and transition requirements of ASU 2016-13. Topic 326 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. Topic 326 will originally become effective for the Company beginning January 1, 2020, with early adoption permitted, on a modified retrospective approach. As a smaller reporting company, the effective date for the Company has been delayed until fiscal years beginning after December 15, 2022, in accordance with ASU 2019-10, although early adoption is still permitted. This standard is not expected to have a material impact to the Company’s consolidated financial statements after evaluation. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this ASU simplify the accounting for income taxes, eliminates certain exceptions to the general principles in Topic 740 and clarifies certain aspects of the current guidance to improve consistent application among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022, though early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. This standard is not expected to have a material impact to the Company’s consolidated financial statements after evaluation.

Convertible Loans

Convertible Loans	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Loans	NOTE 3 – CONVERTIBLE LOANS In December 2019, the Company entered into a series of Convertible Loan Agreements (each a “CLA”) with third parties and certain existing shareholders (the “Lenders”), pursuant to which the Lenders agreed to provide the Company loans in the aggregate amount of $379,000 and in exchange the Company issued to the Lenders (i) convertible promissory notes (the “Notes”) and (ii) warrants with an exercise price of $1.20. In January and March 2020, the Company entered into two additional CLA agreements in the aggregate amount of $135,000, in the same terms. The Notes will bear interest at a rate of 5% per annum. The loan amount represented by the Notes will be repaid to the Lenders according to the following schedule: (i) the principal amount represented by the Notes will be repaid in twenty four equal monthly installments, commencing on the twenty fifth month following the closing of each CLA and (ii) the interest accrued on the loan amount will be paid in two bi-annual installments, commencing on the first anniversary of the first payment of the principal amount. The outstanding loan amount will mature on the earlier of (i) the third anniversary of each CLA or (ii) a deemed liquidation event (as defined therein), and the Lenders may convert all or any portion of the Notes at any time prior to the one-year anniversary of each issuance into shares of Common Stock at a conversion price of US$1.20 per share. In accordance with ASC 815-15-25 the conversion feature was considered embedded derivative instruments, and is to be recorded at their fair value as its fair value can be separated from the convertible loan and its conversion is independent of the underlying note value. The Company recorded finance expenses in respect of the convertible component in the convertible loan in the excess amount of the convertible component fair value over the face loan amount. The conversion liability is then marked to market each reporting period with the resulting gains or losses shown in the statements of operations. As a result of the above issuances, the Company recorded in the periods ended March 31, 2020 and December 31, 2019 a total amounts of US$34,696 and US$97,406, respectively, in respect of the detachable warrants, as a credit to stockholders’ equity (additional paid in capital). The fair value of the Warrants was determined using the Black-Scholes pricing model, assuming a risk free rate of 1.6%, a volatility factor of 54.00 %, dividend yields of 0 % and an expected life of 3 years. During the periods ended March 31, 2020 and December 31, 2019, the Company recorded interest and amortization expenses in the amounts of $16,790 and $4,323, respectively, in respect of the discounts recorded on the debentures.

Stock Options

Stock Options	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Options	NOTE 4 – STOCK OPTIONS The following table presents the Company’s stock option activity for employees and directors of the Company for the three months ended March 31, 2020: Number of Options Weighted Average Exercise Price Outstanding at December 31,2019 1,150,004 0.45 Granted - 0.45 Exercised - - Forfeited or expired (58,333 ) 0.45 Outstanding at March 31,2020 1,091,671 0.45 Number of options exercisable at March 31, 2020 625,002 - The aggregate intrinsic value of the awards outstanding as of March 31, 2020 is US$491,252. These amounts represent the total intrinsic value, based on the Company’s stock price of US$ 0.9 as of March 31, 2020, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date. Costs incurred in respect of stock-based compensation for employees and directors, for the three months ended March 31, 2020 and 2019 were $35,403 and $67,955, respectively

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Parties	NOTE 5 – RELATED PARTIES A. Transactions and balances with related parties Three months ended March 31 2020 2019 General and administrative expenses: Directors compensation (*) 52,002 43,148 Salaries and fees to officers (*) 78,003 26,438 130,005 69,586 (*) share based compensation 39,054 14,811 Research and development expenses: Salaries and fees to officers 25,272 38,139 (*) share based compensation - 4,387 B. Balances with related parties and officers: As of March 31, 2020 2019 Other accounts payables 227,309 128,327

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 6 – SUBSEQUENT EVENTS On May 9, 2020, the Company entered into Securities Purchase Agreement with an existing shareholder (the “Investor”), pursuant to which the Company sold to the Investor for an aggregate amount of $100,000, 91,743 units at a price per unit of $1.09 (the “Units”), whereby each Unit consists of (i) one share of common stock of the Company and (ii) one warrants to purchase one share of Company’s common stock with an exercise price of $1.20 for a period of 36 months following the issuance date.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and with the instructions to Form 10-Q. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the for three-months ended March 31, 2020. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2020. The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates. Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ Alternative Reporting System, for the year ended December 31, 2019
Principles of Consolidation	Principles of Consolidation The consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to the going concern assumptions and convertible loans.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. In November 2018, FASB issued ASU No. 2018-19, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses”, which amends the scope and transition requirements of ASU 2016-13. Topic 326 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. Topic 326 will originally become effective for the Company beginning January 1, 2020, with early adoption permitted, on a modified retrospective approach. As a smaller reporting company, the effective date for the Company has been delayed until fiscal years beginning after December 15, 2022, in accordance with ASU 2019-10, although early adoption is still permitted. This standard is not expected to have a material impact to the Company’s consolidated financial statements after evaluation. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this ASU simplify the accounting for income taxes, eliminates certain exceptions to the general principles in Topic 740 and clarifies certain aspects of the current guidance to improve consistent application among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022, though early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. This standard is not expected to have a material impact to the Company’s consolidated financial statements after evaluation.

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following table presents the Company’s stock option activity for employees and directors of the Company for the three months ended March 31, 2020: Number of Options Weighted Average Exercise Price Outstanding at December 31,2019 1,150,004 0.45 Granted - 0.45 Exercised - - Forfeited or expired (58,333 ) 0.45 Outstanding at March 31,2020 1,091,671 0.45 Number of options exercisable at March 31, 2020 625,002 -

Related Parties (Tables)

Related Parties (Tables)	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Schedule of Transactions and Balances with Related Parties	A. Transactions and balances with related parties Three months ended March 31 2020 2019 General and administrative expenses: Directors compensation (*) 52,002 43,148 Salaries and fees to officers (*) 78,003 26,438 130,005 69,586 (*) share based compensation 39,054 14,811 Research and development expenses: Salaries and fees to officers 25,272 38,139 (*) share based compensation - 4,387 B. Balances with related parties and officers: As of March 31, 2020 2019 Other accounts payables 227,309 128,327

General (Details Narrative)

General (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 180,003	$ 290,815
Working capital	363,886
Accumulated deficit	$ (11,050,155)	$ (10,684,508)

Convertible Loans (Details Narr

Convertible Loans (Details Narrative)	3 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)$ / shares
Convertible Loan Agreements [Member]
Principal amount		$ 379,000
Warrant exercise price per share | $ / shares		$ 1.20
Interest rate		5.00%
Conversion price per share | $ / shares		$ 1.20
Detachable warrants	$ 34,696	$ 97,406
Amortization expenses	$ 16,790	4,323
Convertible Loan Agreements [Member] | Risk Free Interest Rate [Member]
Measurement input, percentage	0.016
Convertible Loan Agreements [Member] | Volatility [Member]
Measurement input, percentage	0.5400
Convertible Loan Agreements [Member] | Dividend Yield [Member]
Measurement input, percentage	0
Convertible Loan Agreements [Member] | Expected Term [Member]
Measurement input, term	3 years
Two Additional Convertible Loan Agreements [Member]
Principal amount		$ 135,000

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Aggregate intrinsic value	$ 491,252
Stock price	$ 0.9
Share based compensation	$ 35,403	$ 67,955
Employees and Directors [Member]
Share based compensation	$ 35,403	$ 67,955

Stock Options - Schedule of Sto

Stock Options - Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning | shares	1,150,004
Number of Options, Granted | shares
Number of Options, Exercised | shares
Number of Options, Forfeited or Expired | shares	(58,333)
Number of Options Outstanding, Ending | shares	1,091,671
Number of Options Exercisable | shares	625,002
Weighted Average Exercise Price, Beginning | $ / shares	$ 0.45
Weighted Average Exercise Price, Granted | $ / shares	0.45
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited or Expired | $ / shares	0.45
Weighted Average Exercise Price, Ending | $ / shares	0.45
Weighted Average Exercise Price, Exercisable | $ / shares

Related Parties - Schedule of T

Related Parties - Schedule of Transactions and Balances with Related Parties (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
General and administrative expense	$ 218,079	$ 163,148
Research and development expense	157,636	131,826
Share based compensation	35,403	67,955
Other accounts payables	227,309	128,327
General and Administrative Expense [Member]
General and administrative expense	130,005	69,586
Share based compensation	39,054	14,811
General and Administrative Expense [Member] | Directors Compensation[Member]
General and administrative expense	52,002	43,148
General and Administrative Expense [Member] | Salaries and Fees to Officers [Member]
General and administrative expense	78,003	26,438
Research and Development Expense [Member]
Share based compensation		4,387
Research and Development Expense [Member] | Salaries and Fees to Officers [Member]
Research and development expense	$ 25,272	$ 38,139

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 09, 2020	Mar. 31, 2020
Common stock exercise price		$ 0.9
Investor [Member] | Securities Purchase Agreement [Member] | Subsequent Event [Member]
Sale of stock, value	$ 100,000
Sale of stock in units	91,743
Sale of stock price per unit	$ 1.09
Common stock exercise price	$ 1.20
Warrant description	One warrants to purchase one share of Company's common stock with an exercise price of $1.20 for a period of 36 months following the issuance date.